Analisi costo/efficacia di sevelamer nel trattamento dell’iperfosforemia del paziente in dialisi. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 5, n. 4, p. 201–218, 2004. DOI: 10.7175/fe.v5i4.809. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/809. Acesso em: 29 oct. 2025.